Elanco Animal Health (ELAN) to Release Earnings on Wednesday

Elanco Animal Health (NYSE:ELAN) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of $0.2692 per share and revenue of $1.3125 billion for the quarter. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. Elanco Animal Health’s revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.37 earnings per share. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Trading Down 0.2%

ELAN traded down $0.05 during trading on Tuesday, hitting $25.67. The company’s stock had a trading volume of 980,648 shares, compared to its average volume of 5,286,421. The firm’s 50 day moving average price is $24.62 and its 200-day moving average price is $24.08. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The stock has a market cap of $12.82 billion, a PE ratio of -51.34, a PEG ratio of 1.72 and a beta of 1.67. Elanco Animal Health has a twelve month low of $13.76 and a twelve month high of $27.72.

Insider Activity

In related news, CEO Jeffrey N. Simmons bought 4,971 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rajeev A. Modi bought 4,911 shares of the stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC grew its position in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in shares of Elanco Animal Health during the fourth quarter worth $41,000. Geneos Wealth Management Inc. boosted its stake in shares of Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after purchasing an additional 2,080 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Elanco Animal Health by 26.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock valued at $91,000 after purchasing an additional 1,332 shares during the period. Finally, UMB Bank n.a. grew its holdings in Elanco Animal Health by 31.9% during the 4th quarter. UMB Bank n.a. now owns 5,609 shares of the company’s stock valued at $127,000 after purchasing an additional 1,358 shares in the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. TD Cowen raised their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.73.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.